Renal Cell Carcinoma Management

Introduction to Management

Patients with renal cell carcinoma should be referred to a urologist who should lead the evaluation and management process, with additional specialist referrals as needed based on disease stage and complexity 1
The American Urological Association (AUA) guidelines state that a urologist should lead the counseling process for patients with renal masses suspicious for renal cell carcinoma 1, 2

Urologists are best positioned to evaluate treatment options including partial nephrectomy, radical nephrectomy, thermal ablation, and active surveillance, and provide comprehensive risk assessment based on tumor size, complexity, imaging characteristics, and patient factors 2
Primary management through surgical interventions (partial or radical nephrectomy), thermal ablation techniques for selected patients, and active surveillance protocols for appropriate candidates 2
Open radical nephrectomy is standard of care for surgical management 3

A multidisciplinary team led by a urologist and including a medical oncologist, radiation oncologist, and interventional radiologist is essential for comprehensive management 3
The medical oncologist is responsible for systemic therapy (immune checkpoint inhibitors, tyrosine kinase inhibitors) 3
The radiation oncologist is responsible for palliative radiation to symptomatic metastatic sites or brain metastases 3

Medical oncology referral is indicated for all patients with metastatic disease requiring systemic therapy, high-risk patients after nephrectomy who may benefit from adjuvant therapy, and patients with intermediate or poor-risk disease requiring combination therapy with nivolumab/ipilimumab 3
Radiation oncology referral is indicated for brain metastases management, palliative treatment of symptomatic metastatic sites, and spinal cord compression 3

The European Society for Medical Oncology (ESMO) guidelines emphasize that management decisions should be based on tumor stage, patient performance status, and risk stratification 3
The American Society of Clinical Oncology (ASCO) recommends that all patients with small renal masses (<4cm) should be considered for renal tumor biopsy when results may alter management 4
Patients with significant comorbidities and limited life expectancy should be considered for active surveillance rather than immediate intervention 4

Delaying nephrology referral in patients with significant renal dysfunction (GFR <45) is not recommended, as it may impact treatment outcomes 3
Nephrology referral is recommended for patients with GFR < 45 ml/min/1.73m², confirmed proteinuria, diabetics with preexisting CKD, or whenever post-intervention GFR is expected to be < 30 ml/min/1.73m² 2
Presence of significant proteinuria, diabetic patient with CKD, anticipated significant decline in GFR post-surgery, complex surgery with high risk of acute kidney injury (AKI), or planned use of nephrotoxic agents may require nephrology referral, despite a GFR > 45 2
Maintaining adequate intravascular volume for renal perfusion, considering avoiding nephrotoxic medications, and monitoring renal function closely in the perioperative period are important for patients with reduced kidney function 2
The European Society of Cardiology (ESC) guidelines recognize that impaired renal function is an independent risk factor for adverse post-operative cardiovascular outcomes 5
Cardiac surgery and intraperitoneal surgery are associated with a higher risk of AKI and may benefit from nephrology input 5, 6
Procedures requiring contrast may warrant nephrology input for renal protection strategies 5

Failing to obtain appropriate imaging for staging (contrast-enhanced CT of chest, abdomen, and pelvis) before specialist referral is a critical error 3
Overlooking the need for renal tumor biopsy in cases where results could alter management decisions is a significant oversight 4
Not considering the long-term renal functional outcomes when planning surgical interventions is essential to avoid unnecessary harm 2
Overreliance on age alone should be avoided, as chronological age should not be the sole determining factor for nephrology referral 7
Failure to recognize AKI risk factors, such as age >56 years, male sex, active cardiac failure, ascites, hypertension, emergency surgery, intraperitoneal surgery, pre-operative creatinine elevation, and diabetes mellitus, can increase AKI risk 5